Instil Bio, Inc.
NASDAQ:TILBiotechnology
+$0.01 today
- Market cap
- $50.53M
- Beta
- 1.91
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$6.99
Volume 0.02M
Average 0.03M
TIL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Instil Bio, Inc.NASDAQ: TIL
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $669K fell 87.5% year over year, behind the +101.3% change in trailing-twelve-month research & development. Sequentially, it fell 80.9% from the prior quarter. Over 3 fiscal years it compounded at -58.6% a year.
Context
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -87.5% toward the trailing-twelve-month pace of +101.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 10M USD
- Year-over-year change
- -15.5%
- 4-year CAGR
- -44.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10M | -15.5% |
| FY2024 | 2024-12-31 | 11.84M | -70.1% |
| FY2023 | 2023-12-31 | 39.6M | -71.9% |
| FY2022 | 2022-12-31 | 141.06M | +31.5% |
| FY2021 | 2021-12-31 | 107.25M | — |
Research & Development vs competitors
How TIL compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +101.3% is the 2nd highest of 9, against a peer median of -22.6%.
- Over three fiscal years its annual growth of -58.6% compares with a peer median of -9.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $135.36M USD | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $108.76M USD | -25.2% | -14.7% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $99.41M USD | +115.1% | +40.7% | — |
| LTM Mar 2026 | $79.04M USD | -54.8% | +4.0% | — | |
| LTM Mar 2026 | $36.3M USD | -40.4% | -24.8% | 3629.9% | |
| LTM Mar 2026 | $32.14M USD | +45.7% | -7.4% | 428.8% | |
| LTM Mar 2026 | €22.87M EUR | -34.8% | -11.8% | 77989.1% | |
| LTM Mar 2026 | $20.04M USD | +101.3% | -58.6% | — | |
| LTM Mar 2026 | CA$19.63M CAD | +4.7% | +15.5% | — | |
| Peer median (excluding TIL) | — | -22.6% | -9.6% | 2029.4% | |
Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 5.99M | 0 | 0 | 534K |
| Gross Profit | 0 | (5.99M) | 0 | 0 | (534K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 107.25M | 141.06M | 39.6M | 11.84M | 10M |
| Selling, General & Admin | 51.31M | 62.24M | 47.55M | 44.21M | 27.22M |
| Operating Expenses | 155.56M | 200.18M | 159.17M | 73.54M | 52.37M |
| Depreciation & Amortization | 2.75M | 5.99M | 4.76M | 3.61M | 534K |
| EBITDA | (152.51M) | (217.38M) | (147.12M) | (62.53M) | (65.01M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (155.56M) | (206.17M) | (159.17M) | (73.54M) | (52.91M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 80K | 3.66M | 8.87M | 6.99M | 3.86M |
| Interest Expense | 0 | 1.88M | 5.21M | 8.99M | 5.83M |
| Other Income / Expenses | (1.2M) | (19.08M) | 3.08M | (594K) | (18.47M) |
| Income Before Tax | (156.76M) | (225.25M) | (156.09M) | (74.14M) | (71.37M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 39K | (2.07M) | 0 | 0 | 0 |
| Net Income | (156.79M) | (223.18M) | (156.09M) | (74.14M) | (71.37M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (29.60) | (34.46) | (24.00) | (11.39) | (10.70) |
| EPS (Diluted) | (29.60) | (34.46) | (24.00) | (11.39) | (10.70) |
| Weighted Avg Shares | 5.3M | 6.48M | 6.5M | 6.51M | 6.67M |
| Weighted Avg Shares (Diluted) | 5.3M | 6.48M | 6.5M | 6.51M | 6.67M |
Instil Bio, Inc.
NASDAQ:TIL
Intrinsic Alpha fair value
Locked
Current Price
$7.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.